Antipsychotics Rarely Cause Persistent QTc Prolongation in Children and Adolescents

Reevaluating Cardiac Surveillance in Pediatric Psychopharmacology

The clinical use of antipsychotic medications in children and adolescents has expanded significantly to manage a broad spectrum of neurodevelopmental and behavioral conditions [1, 2]. While these agents are effective for stabilizing severe symptoms, they are frequently associated with metabolic and cardiovascular concerns that complicate long-term management [3, 4]. Among these risks, the potential for drug-induced QTc prolongation (a delay in the heart's electrical recharging system that can predispose patients to arrhythmias) remains a primary focus of clinical anxiety due to its association with life-threatening ventricular events. Current practice often mandates rigorous electrocardiographic screening, yet the real-world incidence of clinically significant cardiac events in the pediatric population remains poorly defined [5]. A new study now offers data-driven insights into the frequency and persistence of these cardiac findings in a large naturalistic cohort of young patients.

Cohort Characteristics and Monitoring Methodology

The researchers conducted a single-center, observational cohort study that tracked patients younger than 18 years who were treated with antipsychotic medications between January 2020 and December 2024. This longitudinal analysis included a total of 430 patients, a population characterized by a notable male predominance of 79.1% and a mean age of 11.3 ± 3.35 years. To ensure diagnostic accuracy and data integrity, the study protocol required each participant to have at least one 12-lead electrocardiogram (ECG) performed during the course of their treatment, which also had to be accompanied by a formal cardiology report. Of the initial cohort, analyzable ECG data were available for 429 of the 430 patients, providing a robust dataset for evaluating cardiac safety in a real-world clinical setting. The researchers utilized Bazett’s formula (a standard mathematical correction that adjusts the measured QT interval to account for the patient's heart rate) to calculate the corrected QT interval (QTc). To account for physiological differences in pediatric development and minimize the risk of false positives, these QTc values were interpreted using sex-specific reference thresholds. This methodological framework allowed the authors to distinguish between transient fluctuations and clinically relevant deviations in cardiac repolarization, which is the phase where the heart's ventricles recover after a contraction.

Frequency and Nature of Electrocardiographic Deviations

The analysis of cardiac monitoring data revealed that numeric deviations on electrocardiograms are a common occurrence in pediatric patients managed with antipsychotic medications. At the patient level, 195 of 429 patients (45.5%) exhibited at least one numeric ECG abnormality during the follow-up period. Despite this high frequency of objective findings, the researchers concluded that these ECG abnormalities were relatively frequent but predominantly mild, transient, and clinically benign. The most common numeric ECG abnormalities identified in the cohort were heart rate abnormalities, which often represent physiological fluctuations rather than primary cardiac pathology. Specific attention was paid to the corrected QT interval (QTc), a measure of the time it takes for the heart's ventricles to electrically recharge. The study found that QTc prolongation above sex-specific thresholds was observed in 24 patients (5.6%). Crucially, these findings were rarely sustained over time. The researchers determined that QTc prolongation was persistent in only 5 cases, representing 20.8% of those with an initial prolongation. Persistence was strictly defined as the occurrence of an abnormal interval in at least two separate ECG recordings. This low rate of recurrence suggests that the majority of observed QTc deviations in this population are isolated events rather than indicative of a stable drug-induced cardiac risk, which may reduce the need for immediate medication discontinuation in asymptomatic patients.

Absence of Severe Arrhythmias and Clinical Risk Factors

The clinical safety profile observed in this cohort suggests that the risk of life-threatening cardiac events is exceptionally low during pediatric antipsychotic treatment. No patient exhibited a QTc interval of 500 ms or greater, a threshold often used in clinical practice to indicate a high risk for torsades de pointes (a specific, dangerous type of ventricular tachycardia). Furthermore, the researchers reported that no clinically significant ventricular arrhythmias were observed throughout the study period. The data also showed that no high-grade conduction disturbances were observed, which are serious electrical blocks, such as third-degree heart block, that can severely impair the heart's pumping efficiency. Most importantly for clinicians managing these patients, no sudden cardiac events were observed, reinforcing the conclusion that while minor electrocardiogram changes are common, they rarely translate into acute clinical emergencies. In an effort to identify specific patient populations at higher risk, the researchers performed an exploratory comparison between patients with and without QTc prolongation. The analysis demonstrated that QTc prolongation was not significantly associated with sex or age, suggesting that demographic factors do not reliably predict which children will develop these deviations. Pharmacological variables also failed to show a strong correlation with cardiac risk. Specifically, QTc prolongation was not significantly associated with antipsychotic polypharmacy (the use of multiple antipsychotic drugs simultaneously). Similarly, the researchers found that QTc prolongation was not significantly associated with combined first- and second-generation antipsychotic exposure. Even when considering external pharmacological influences, QTc prolongation was not significantly associated with QT-relevant comedications, which are other drugs known to affect the QT interval. These findings suggest that the cardiac impact of antipsychotics in children may be less sensitive to drug-drug interactions and dosing complexity than previously hypothesized.

Shifting Toward Risk-Based Cardiac Screening

The clinical data from this large naturalistic pediatric cohort suggest that while numeric electrocardiographic deviations are relatively common, they are largely clinically insignificant. The researchers observed that ECG abnormalities during antipsychotic treatment were relatively frequent but predominantly mild, transient, and clinically benign. This conclusion is supported by the fact that QTc prolongation occurred in only 24 of 429 patients (5.6%) and was persistent in only 5 cases (20.8%). Because these changes rarely persisted or reached dangerous thresholds, such as the 500 ms mark, the actual risk of developing a life-threatening arrhythmia appears lower than historical concerns might suggest. Given that QTc prolongation occurred in a small minority of patients and was not associated with adverse cardiac outcomes, the necessity of universal screening protocols is being reevaluated. The researchers suggest that the current practice of mandatory, frequent electrocardiograms for every pediatric patient on antipsychotics may be unnecessary in the absence of other risk factors. Instead, the findings support a selective, risk-based approach to ECG monitoring rather than routine universal screening. This strategy allows clinicians to focus resources on patients with known pre-existing cardiac conditions, those with a family history of sudden death, or those presenting with clinical symptoms such as syncope (fainting) or palpitations. For the practicing physician, transitioning to a risk-based model could significantly reduce the logistical and financial burden on both the healthcare system and the families of pediatric patients. By moving away from universal screening, clinicians can avoid the potential for false positives and the subsequent unnecessary anxiety or treatment interruptions that often follow transient, benign electrocardiographic changes. This evidence-based shift allows for a more streamlined clinical workflow while maintaining patient safety through targeted surveillance of high-risk individuals.

References

1. Jensen PS, Buitelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.. European child & adolescent psychiatry. 2007. doi:10.1007/s00787-006-0580-1

2. Dias MF, Nogueira YJDA, Romano-Silva MA, Miranda DMD. Effects of antipsychotics on the gastrointestinal microbiota: A systematic review.. Psychiatry research. 2024. doi:10.1016/j.psychres.2024.115914

3. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis. World Psychiatry. 2015. doi:10.1002/wps.20252

4. Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet Psychiatry. 2019. doi:10.1016/s2215-0366(19)30416-x

5. Benarous X, Cottin G, Lahaye H, et al. Efficacy, Tolerability, and Acceptance of Long-Lasting Antipsychotics in Children and Adolescents: A Systematic Review.. Journal of child and adolescent psychopharmacology. 2022. doi:10.1089/cap.2021.0124